The Norwegian Institute of Public Health recently identified a mutation in 2009 H1N1 influenza virus isolated from two patients who died and one with severe disease. It has been suggested that this mutation, which causes a change from the amino acid aspartic acid to glycine at position 225 of the viral HA protein (D225G), could …
The D225G change in 2009 H1N1 influenza virus is not a concern Read More »
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Gustavo Palacios, and Mady Hornig A TWiV panel of five considers the finding of Streptococcus pneumoniae in fatal H1N1 cases in Argentina, hysteria in the Ukraine over pandemic influenza, and human vaccinia infection after contact with a raccoon rabies vaccine bait. [powerpress url=”http://traffic.libsyn.com/twiv/TWiV059.mp3″] Click the arrow above to …
As week 46 of 2009 comes to a close, the Centers for Disease Control and Prevention reports that influenza has peaked in the US. That conclusion is based on the agency’s influenza surveillance program, summarized in this figure: Does this mean that pandemic influenza is over? Absolutely not. This is just the second wave, sparked …
A number of readers have asked when we would have information about the safety of the influenza 2009 H1N1 vaccine. The World Health Organization has just released briefing note #16 “Safety of pandemic vaccines” in which they summarize vaccination information from 16 countries in which 80 million doses of vaccine have been administered. Side effects …
Although the influenza 2009 H1N1 vaccine produced by Novartis, Fluvirin, was previously approved for use in the US, the clinical data supporting its safety and immunogenicity had not been released. The company has now issued a media release containing interim clinical data on the effects of the vaccine in humans. According to the company, testing …
The emergence of oseltamivir (Tamiflu)-resistant 2009 H1N1 influenza virus in a Canadian family illustrates the basic concept that viral loads depend on the dose of antiviral drug. Neuraminidase inhibitors like Tamiflu and Relenza are used to treat severe illness caused by the 2009 pandemic influenza A (H1N1) virus. The antiviral drugs may also be used …
Tamiflu-resistant pandemic influenza H1N1 virus selected by prophylaxis Read More »
